B+
Bull case
30%
Probability
Target price
$68.00
+23.4% vs current
LQDA
LiquidiaANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
45%
Probability
Target price
$56.00
+1.6% vs current
B-
Bear case
25%
Probability
Target price
$38.00
-31.0% vs current
AI sentiment snapshot
Latest data as of 2026-05-14
Recent news sentiment (30D)
+0.7
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+48.8
Score
AI commentary
Post-earnings tone is positive but no longer early. Company-source evidence clearly improved on May 11, 2026, and secondary coverage framed the print as a revenue/EPS beat with modestly positive immediate price reaction. By the May 13, 2026 anchor close of $57.59, however, the stock had already moved to around the revised analyst target area seen in secondary follow-ups, while broad sell-side revision coverage still looks thin. That keeps the setup constructive but better described as a monitored high-expectation name than a fresh undiscovered re-rating.
RankAlpha Sentiment Codex - 2026-05-14
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-11catalystQ1 earnings reset around YUTREPIA commercial strengthHigh impact
Q1 results attached to the May 11, 2026 8-K showed YUTREPIA net product sales of about $129.9M, roughly 44% Q/Q growth, third consecutive quarter of profitability, and cash rising to $222.8M; management also disclosed more than 4,500 unique prescriptions and about 3,750 treated patients since launch, which materially strengthened the near-term earnings base [#8-K-2026-05-11].
2026-08-12event2026 PH-ILD and franchise-expansion study progressHigh impact
The company presentation filed with the May 11, 2026 8-K said Liquidia is recruiting ASCENT Cohort B Tyvaso transition patients and recruiting the global Phase 3 Re-Spire study for L606 in PH-ILD while advancing IPF/PPF, PH-COPD, and SSc-Raynaud's programs; credible enrollment or execution progress could extend the story beyond the initial YUTREPIA launch [#8-K-2026-05-11].
2026-12-31catalystSelf-funded commercial scale can support broader pipeline spendHigh impact
Liquidia's Q1 release and 10-Q showed profitability, $222.8M of cash at March 31, 2026, and higher R&D spending driven partly by L606 and YUTREPIA development work, supporting a view that the company can fund broader prostacyclin franchise expansion without an immediate financing need, though the setup still depends on sustaining launch momentum [#8-K-2026-05-11] [#10-Q-2026-05-11].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-14 • Updated nightlySource: Internal modelMethodology